The GSK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GSK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The GSK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View GSK Detailed Price Forecast - CNN Money||View GSK Detailed Summary - Google Finance|
|View GSK Detailed Summary - Yahoo! Finance||View GSK Stock Research & Analysis - Zacks.com|
|View GSK Trends & Analysis - Trade-Ideas||View GSK Major Holders - Barrons|
|View GSK Call Transcripts - NASDAQ||View GSK Breaking News & Analysis - Seeking Alpha|
|View GSK Annual Report - CompanySpotlight.com||View GSK OTC Short Report - OTCShortReport.com|
|View GSK Fundamentals - TradeKing||View GSK SEC Filings - Bar Chart|
|View Historical Prices for GSK - The WSJ||View Performance/Total Return for GSK - Morningstar|
|View the Analyst Estimates for GSK - MarketWatch||View the Earnings History for GSK - CNBC|
|View the GSK Earnings - StockMarketWatch||View GSK Buy or Sell Recommendations - MacroAxis|
|View the GSK Bullish Patterns - American Bulls||View GSK Short Pain Metrics - ShortPainBot.com|
|View GSK Stock Mentions - StockTwits||View GSK Stock Mentions - PennyStockTweets|
|View GSK Stock Mentions - Twitter||View GSK Investment Forum News - Investor Hub|
|View GSK Stock Mentions - Yahoo! Message Board||View GSK Stock Mentions - Seeking Alpha|
|View Insider Transactions for GSK - SECform4.com||View Insider Transactions for GSK - Insider Cow|
|View GSK Major Holdings Summary - CNBC||View Insider Disclosure for GSK - OTC Markets|
|View Insider Transactions for GSK - Yahoo! Finance||View Institutional Holdings for GSK - NASDAQ|
|View GSK Stock Insight & Charts - FinViz.com||View GSK Investment Charts - StockCharts.com|
|View GSK Stock Overview & Charts - BarChart||View GSK User Generated Charts - Trading View|
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
Posted on Friday June 22, 2018
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Mylan Stock Looks Cheap, but Don’t Overlook These Risks
Posted on Thursday June 21, 2018
Mylan N.V. (NASDAQ:MYL) has been a battleground stock in 2018. EpiPen is a perfect example. The brand brought Mylan shame and a substantial fine, but it’s also in short supply now, continuing to lead to strong ongoing profits.
Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player
Posted on Wednesday June 20, 2018
GlaxoSmithKline Plc’s HIV venture wants to use less burdensome forms of treatment to unseat rival Gilead Sciences Inc. and become the top player in the $26 billion-a-year market in the mid-2020s. “If our pipeline and our competitors’ pipelines play out as we’re expecting, that’s our aim,” Deborah Waterhouse, chief executive officer of ViiV Healthcare, told journalists at a briefing Wednesday in London. Glaxo and partner Pfizer Inc. are taking on Gilead with a strategy to develop two-drug HIV combinations rather than the three-drug regimens that have been the standard for many years.
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
Posted on Wednesday June 20, 2018
GlaxoSmithKline (GSK.L) is taking its fight with Gilead Sciences (GILD.O) for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment. The drugmakers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Deborah Waterhouse, head of GSK's majority-owned HIV business ViiV Healthcare, aims to overtake Gilead as market leader in the $26 billion-a-year (19.8 billion pounds) HIV market by the mid-2020s, assuming the gamble on two-drug combinations pans out.